- Citations, last 5 years
- 8
- Works, last 5 years
- 3
- h-index
- 17
- Scientists listed
- 2
- Grants since 2016
- 21
Grants received
2025–2026 · research · R41
Development of PAR2 Pepducins for the Treatment of COPD
Lidija Covic · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2025 · research · R42
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2025 · research · R42
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2025 · research · R42
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2022–2023 · research · R41
Development of liver homing PAR2 pepducins for the treatment of Hepatocellular Carcinoma
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2022 · research · R41
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats
Sridhar G Prasad · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2023 · research · R43
Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats
Albert Remacle · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2023 · research · R43
Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts
Sambaiah Thota · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts
Santosh C. Sinha · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2018–2021 · research · R42
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2018 · research · R42
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2018–2021 · research · R42
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2018 · research · R41
Development of PAR4 Pepducins as a Novel Antithrombotic Treatment
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2024 · research · R44
Advancing CAP4196 into in vivo Proof of Concept Translational Studies
Albert Remacle · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2022 · research · R44
Advancing CAP4196 into in vivo Proof of Concept Translational Studies
Sridhar G Prasad · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2019 · research · R43
Small molecule activators of alpha-crystallin for non-surgical treatment of cataracts
Sridhar G Prasad · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Small molecule activators of alpha-crystallin for non-surgical treatment of cataracts
Sridhar G Prasad · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2013–2020 · research · R44
Development of PAR2 Pepducins as a Novel NASH Treatment
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2013–2024 · research · R44
Development of PAR2 Pepducins as a Novel NASH Treatment
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
2013–2020 · research · R44
Development of PAR2 Pepducins as a Novel NASH Treatment
Athan Kuliopulos · Plex Pharmaceuticals (United States) · funded by National Institutes of Health
